Immunoglobulin Prophylaxis in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis
- 10 February 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (5), 770-781
- https://doi.org/10.1200/jco.2008.16.8450
Abstract
Purpose: Because the role of immunoglobulins (IVIG) prophylaxis in patients undergoing hematopoietic stem-cell transplantation (HSCT) has not been established in terms of survival and infection prevention, we conducted a meta-analysis evaluating these issues. Methods: Systematic review and meta-analysis of randomized-controlled trials comparing prophylaxis with polyvalent IVIG or cytomegalovirus (CMV)-IVIG and control or another preparation or dose. PUBMED, Cochrane Library, LILACS, and conference proceedings were searched. Two reviewers appraised the quality of trials and extracted data. Relative risks (RRs) with 95% CIs were estimated and pooled. Results: Thirty trials including 4,223 patients undergoing bone marrow transplantation (BMT) were included. There was no difference in all-cause mortality when polyvalent IVIG or CMV-IVIG was compared to control (RR, 0.99; 95% CI, 0.88 to 1.12; and RR, 0.86; 95% CI, 0.63 to 1.16, respectively). There was no difference in clinically documented infections when polyvalent IVIG was compared with control (RR, 1.00; 95% CI, 0.90 to 1.10; five trials). CMV infections were not significantly reduced with either polyvalent IVIG or CMV-IVIG. Interstitial pneumonitis was reduced with polyvalent IVIG in older studies but not in the more recent ones, nor in studies assessing CMV-IVIG. Polyvalent IVIG increased the risk for veno-occlusive disease (RR, 2.73; (95% CI, 1.11 to 6.71). Graft-versus-host disease was not affected. Conclusion: Because there is no advantage in terms of survival or infection prevention, IVIG does not have a role in HSCT.Keywords
This publication has 35 references indexed in Scilit:
- Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation?Annals of Internal Medicine, 2003
- A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantationBone Marrow Transplantation, 2001
- Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind TrialAnnals of Internal Medicine, 1993
- Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patientsBlood, 1992
- Immunomodulatory and Antimicrobial Efficacy of Intravenous Immunoglobulin in Bone Marrow TransplantationNew England Journal of Medicine, 1990
- Consensus on IVIGThe Lancet, 1990
- Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow TransplantationAnnals of Internal Medicine, 1987
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationNew England Journal of Medicine, 1986
- Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin: Randomized trial in bone marrow transplant recipientsAmerican Journal Of Medicine, 1984
- Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation: Preliminary results of a controlled trialAmerican Journal Of Medicine, 1984